Abstract: The CCL15 is a human CC chemokine that activates the receptors, CCR1 and CCR3. Unlike other chemokines, it contains an unusually long N-terminal domain of 31 amino acids preceding the first cysteine residue and a third disulfide bond. To elucidate the functional role of distinct structural determinants, a series of sequential amino-terminal truncated and point-mutated CCL15 derivatives as well as mutants lacking the third disulfide bond and the carboxy-terminal a-helix were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. We demonstrate that a truncation of 24 amino acid residues (D24-CCL15) converts the slightly active 92-residue D0-CCL15 into a potent agonist of CC chemokine receptor 1 (CCR1) and a weak agonist of CCR3 in cellbased assays. The biological activity decreases from D24-CCL15 to D29-CCL15, and re-increases from D29-CCL15 to D30-CCL15. Thus, an exocyclic N-terminal region of only one amino acid residue is sufficient for efficient CCR1 activation. As none of the peptides investigated except for D24-CCL15 activates CCR3, we suggest that CCR1 is the major receptor for CCL15 in vivo. Further we demonstrate that the third disulfide bond of CCL15 and an exchange of tyrosine in position 70 by a leucine residue, which is conserved in CXC chemokines, do not alter the interaction with CCR1. In contrast, a CCL15 derivative lacking the carboxy-terminal a-helix exhibits a complete loss of tertiary structure and hence loss of CCR1 agonistic and binding activity. This study demonstrates that specific protein residues in chemokines, which contribute to receptor-ligand interaction, vary significantly between chemokines and cannot be extrapolated using data from functionally related chemokines. 
Introduction
Chemokines are small, constitutively expressed or inducible chemotactic cytokines of 6-10 kDa. They are mainly involved in leukocyte attraction and activation, and play a central role in the pathogenesis of several inflammatory diseases (1, 2) . Over 50 chemokines have been identified so far. The primary structure is generally characterized by a pattern of four conserved cysteines. Depending on the absence or presence of one amino acid residue separating the two NH 2 -terminal cysteines, two major subfamilies are distinguished, the CC and CXC chemokines.
Chemokines signal through G protein-coupled receptors, and some of these receptors, CCR5 and CXCR4, are required as co-receptors for HIV infection (3, 4) . All chemokines exhibit a highly similar tertiary fold consisting primarily of a flexible region NH 2 -terminally located to the CC or CXC motif (NH 2 -terminus) followed by a first loop region (N-loop), three antiparallel b-strands and a COOH-terminal a-helix. The molecular mechanisms underlying the chemokine/chemokine receptor interaction thus contributing to the tightly controlled inflammatory response of the redundant chemokine system are not yet completely understood (5-7).
The primary structure of CCL15 (HCC-2, leukotactin-1, MIP-1d, MIP-5) was initially deduced from the cDNA of an expressed sequence tag clone by molecular cloning and from a bicistronic CCL14/15 mRNA (8) . Prediction of a secretory signal peptide suggests a mature protein of 92 amino acid residues which contains an unusually long NH 2 -terminal domain preceding the first cysteine residue.
A specific feature of CCL15 is a third disulfide bond, a structural element also only contained in the CC chemokines CCL23/CKb-8 and CCL1/I-309. Nuclear magnetic resonance (NMR)-spectroscopic structure determination of CCL15 has confirmed that this additional disulfide bond does not influence the typical chemokine structure (9) .
Using recombinantly expressed and synthetic peptides, itwas shown that CCL15 binds to and activates the chemokine receptors CCR1 and CCR3, and induces chemotaxis and calcium mobilization in monocytes, eosinophils, neutrophils and lymphocytes (10) (11) (12) (13) . Recently, it was suggested that CCL15 is involved in atherosclerosis (14) . In addition, the mechanism of CCL15-induced chemotaxis through CCR1 in human osteogenic sarcoma cells was investigated (15) . However, its precise physiologic role and the structure of naturally occurring molecular forms remain to be determined.
Mutational studies of several chemokines suggested a two-step model in which the N-loop of the ligand initially binds to the receptor and then the NH 2 -terminal domain interacts with the receptor resulting in its activation (16) (17) (18) . According to this separation of binding and activation functions between N-loop and NH 2 -terminus it has been demonstrated for several chemokines such as CCL5/ RANTES (19, 20) , CCL3/MIP-1a (21) , CCL2/MCP-1 (22, 23) , CCL7/MCP-3 (24) , CXCL12/SDF-1a (16) and CCL23/CKb8 (25) that the biological activity is tightly regulated by the length of the NH 2 -terminus. Truncation, elongation or substitution within this region can cause a change of receptor selectivity, altered binding affinity or even a switch from agonistic to antagonistic properties. However, a detailed determination of amino acid residues which contribute to the activation and binding of CCL11 to CCR3 demonstrate that these residues are distributed throughout the NH 2 -terminus and N-loop indicating that the chemokine/receptor interaction is more complex (26) .
In the present study, we have investigated the functional and structural importance of characteristic structural elements of CCL15. For this purpose, a series of NH 2 -terminally truncated CCL15 derivatives and suitable CCL15 analogs were chemically synthesized (Fig. 1) . As most of the known active CC chemokines have a relatively short NH 2 -terminal region the series of NH 2 -terminal truncated derivatives started with D24-CCL15. Its NH 2 -terminus consists of seven amino acid residues. These peptides were used to investigate the role of the NH 2 -terminal exocyclic domain, the third disulfide bond, the COOH-terminal a-helical domain and of residue Leu70 in order to establish a structure-activity relation with the chemokine receptors CCR1 and CCR3. 
Disulfide bond formation
To introduce the disulfide bonds, the oxidative folding of CCL15 derivatives was carried out in the presence of the redox system cysteine/cystine as reported earlier (27 
NMR spectroscopy
One-and two-dimensional NMR-spectroscopic analysis of CCL15 peptides was carried out as reported earlier (9).
Aequorin assay
The CHO-K1 cell lines expressing chemokine receptor 
Results

Synthesis of CCL15 analogs
Recently we reported the Fmoc-based synthesis of D26- To obtain the derivative D26-[Ala64,Asp98]CCL15-D15
( Fig. 1) , an acid-labile Asp-Pro cleavage site was inserted into the sequence of CCL15 by a Gly98Asp substitution (30, 31) . The reduced peptide D26-[Ala64,104,Asp98]CCL15
obtained from solid-phase peptide synthesis was treated with acetic acid at 95°C. After 1 h, three products cor-
Asp98]CCL15 and D31-[Ala64,Asp98]CCL15-D15 were identified by LCMS analysis, indicating that Asp98-Pro99
and Asp52-Cys53 peptide bonds are acid-labile under the conditions used (Fig. 2) . After c. 4 h, the fully cleaved peptide D31-[Ala64,Asp98]CCL15-D15 was exclusively obtained (Fig. 2) . However, the desired COOH-terminally truncated derivative D26-[Ala64,Asp98]CCL15-D15 was isolated after 45 min at 90°C and subjected to oxidative folding. HPLC analysis of the folding reaction revealed a complex mixture of disulfide isomers suggesting that the COOH-terminal a-helix contributes to the highly selective folding process of CCL15. Alternatively, D26- (Fig. 2) , indicating that the Asp52-Cys53 peptide bond is significantly stabilized in the presence of the intact tertiary structure.
Structure
The tertiary structure of D-26CCL15 was recently solved by one-and two-dimensional NMR spectroscopy (9) . The one-dimensional The activities of CCL15 derivatives were tested on CHO-K1 cells stably transfected with CCR1 or CCR3, using an aequorin-based Ca(II)-release assay (Fig. 4 , exhibited a significantly decreased heparin-binding affinity -fluxes of selected derivatives were determined using freshly isolated human monocytes. Data represent 4 experiments using monocytes of 4 different donors.
Escher et al . Structure-activity relation of the chemokine CCL15/HCC-2 and were eluted at 220, 275, and 220 mm NaCl respectively.
However, all CCL15 analogs bound to heparin in the presence of NaCl at physiological concentrations.
Discussion
Since naturally occurring molecular forms of CCL15 have not been identified, the NH 2 -terminal length of the functional peptide remains speculative and may range from D0-CCL15 with 92 amino acids to D30-CCL15 containing 62 residues. To investigate the functional importance of the NH 2 -terminal domain, a series of truncated CCL15 derivatives was chemically synthesized. We presumed that a sequential truncation of the NH 2 -terminus from D24-CCL15 to D30-CCL15 lead to a putative chemokine receptor antagonist. Starting with D26-CCL15 which was initially produced after recombinant expression of CCL15 in insect cells (11) , these peptides were compared with the largest CCL15 analog, D0-CCL15 . Up to now, the activity of D0-CCL15 has been described by several groups with some inconsistent results. On CCR1-transfected cells, full crossdesensitization of this receptor was observed with CCL3/ MIP-1a and partial cross-desensitization with CCL11/ eotaxin on CCR3 (11). However, another group reported that D0-CCL15 induced Ca(II)-fluxes on CCR1, but failed to induce Ca(II)-fluxes in CCR3 transfectants (12) . Using radioligand binding and calcium mobilization assays, we comprehensively demonstrate that D0-CCL15 exhibits only a weak affinity to and activation of CCR1, and is to be considered as a partial agonist of this receptor, whereas it is inactive on CCR3. These findings are consistent with recently reported results using some selected recombinantly expressed NH 2 -terminally truncated CCL15 derivatives (37) .
We have further demonstrated that the NH 2 -terminal deletion of 24 amino acid residues transforms D0-CCL15 to a potent high-affinity agonist of CCR1 and a weak agonist of In the present study, we show that the sequential NH 2 -terminal truncation of D24-CCL15 to D29-CCL15 slightly decreases the binding and functional properties of CCL15 on CCR1 but does not abolish it. These findings are in contradiction with recent results describing that D29-CCL15 neither binds nor activates CCR1 (37) . Furthermore, the variant D30-CCL15 exhibits a partially recovered biological activity on transfected cell lines and on freshly isolated human monocytes. Thus, an NH 2 -terminal domain consisting of only one amino acid residue (aspartic acid) is sufficient for the agonistic activity of CCL15. To our knowledge, CCL15 is the first chemokine not exhibiting significantly reduced agonistic activity upon deletion of the NH 2 -terminal domain.
These results suggest that the truncation of NH 2 -terminal Table 1 ). D29-CCL15 shows a submaximal Ca-mobilization. Data points represent the mean ± SEM of four experiments with monocytes isolated from four different donors. Measurements were performed in triplicate. (B) D0-CCL15 and D29-CCL15 are less potent chemoattractants with a maximal migration at 10 nm than D24/26 and D30-CCL15 (maximal migration observed at 1 nm). Data points represent the mean ± SEM of five different experiments with monocytes isolated from five different donors. The chemotaxis experiments were performed in triplicate.
residues represents an important mechanism for the tight regulation of CCL15-induced recruitment of immune cells during inflammatory processes. We propose that the unusually large but nonfunctional CC chemokine D0-CCL15 serves as a precursor of active CCL15-derived peptides in vivo and is probably activated by specific proteolytic processing.
As only D26-CCL15 was partially active on CCR3, we suggest that CCR1 is the predominant receptor of CCL15. 
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The following material is available from http://www. blackwellpublishing.com/products/journals/suppmat/JPP/ JPP102/JPP102sm.htm Figure S1 . Schematic ribbon drawing indicating the elements of regular secondary structure of CCL15 determined using NMR-spectroscopy (see reference 9 of the manuscript). The characteristic b-sheet region is shown in yellow, the a-helical regions are in red. In addition, the amino acids A47, K21, T39, V45, and F37 are marked in blue and are located within the b-sheet region.
